XNCR
Xencor Inc

733
Mkt Cap
$942.18M
Volume
0.00
52W High
$27.24
52W Low
$6.92
PE Ratio
-5.46
XNCR Fundamentals
50D MA
$10.44
Beta
1.26
Avg. Volume
1.2M
EPS (Annual)
-$3.58
P/B
1.52
Rev/Employee
$441,972.00
Loading...
Loading...
News
all
press releases
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the...
Business Wire·18h ago
News Placeholder
More News
News Placeholder
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on...
Business Wire·4d ago
News Placeholder
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...
PR Newswire·8d ago
News Placeholder
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation...
Business Wire·11d ago
News Placeholder
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
chainwire·6mo ago
News Placeholder
Xencor Reports Third Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for...
Business Wire·1y ago
News Placeholder
Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated...
Business Wire·1y ago

Latest XNCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.